Pancreatic/Thyroid/Other Endocrine Cancers
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor.
"We believe we've developed the first prognostic model that, once confirmed in larger studies, could provide a critical decision-making tool for clinicians," said lead author Gregory Russell Pond, PhD.
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
Lutathera is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Azedra, a high-specific-activity radiotherapeutic product, is a substrate for the norepinephrine reuptake transporter that is highly expressed on the cell surface of neuroendocrine tumors.
The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.
There was a 6.2-fold difference in thyroidectomy rates across U.S. regions (range, 22 to 139 per 100,000 Medicare beneficiaries).
Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.
The researchers found that the men with early-stage prostate cancer who did not already have cardiovascular disease, but who received ADT had an 81% higher risk for heart failure.
The researchers reported the resensitization of chemoresistant PDAC cells by curcumin through inhibition of the PRC2-PVT1-c-Myc axis.
Clinical trials of pamrevlumab are currently ongoing for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.
That FDA has approved Xermelo (telotristat ethyl) tablets as the first oral treatment for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Regular aspirin use is associated with reduced risk of pancreatic cancer in a Chinese cohort, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.
For patients with papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference, according to a study published online in the Journal of Clinical Oncology.
For pancreatic ductal adenocarcinoma (PDAC) patients with diabetes, metformin treatment was associated with an increase in survival. Those were the findings of a new study published in the American Journal of Gastroenterology.
AstraZeneca announced that the FDA has granted Orphan Drug designation to selumetinib for the adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
Mission Pharmacal announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for over-the-counter liquid Potassium Iodide Oral Solution for use in the event of a nuclear emergency.
Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.
Novartis' Afinitor (everolimus) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.
A new international, multicenter study has found that incretin-based drugs, used to treat type 2 diabetes, are not associated with an increased risk of pancreatic cancer.